Unknown

Dataset Information

0

Identification of ongoing human immunodeficiency virus type 1 (HIV-1) replication in residual viremia during recombinant HIV-1 poxvirus immunizations in patients with clinically undetectable viral loads on durable suppressive highly active antiretroviral therapy.


ABSTRACT: In most human immunodeficiency virus type 1 (HIV-1)-infected individuals who achieve viral loads of <50 copies/ml during highly active antiretroviral therapy (HAART), low levels of plasma virus remain detectable for years by ultrasensitive methods. The relative contributions of ongoing virus replication and virus production from HIV-1 reservoirs to persistent low-level viremia during HAART remain controversial. HIV-1 vaccination of HAART-treated individuals provides a model for examining low-level viremia, as immunizations may facilitate virus replication and sequence evolution. In a phase 1 trial of modified vaccinia virus Ankara/fowlpox virus-based HIV-1 vaccines in 20 HIV-infected young adults receiving HAART, we assessed the prevalence of low-level viremia and sequence evolution, using ultrasensitive viral load (<6.5 copies/ml) and genotyping (five-copy sensitivity) assays. Viral evolution, consisting of new drug resistance mutations and novel amino acid changes within a relevant HLA-restricted allele (e.g., methionine, isoleucine, glutamine, or arginine for leucine at position 205 of RT), was found in 1 and 3 of 20 subjects, respectively. Sequence evolution was significantly correlated with levels of viremia of between 6.5 and <50 copies/ml (P = 0.03) and was more likely to occur within epitopes presented by relevant HLA alleles (P < 0.001). These findings suggest that ongoing virus replication contributes to low-level viremia in patients on HAART and that this ongoing replication is subject to CD8(+) T-cell selective pressures.

SUBMITTER: Shiu C 

PROVIDER: S-EPMC2748010 | biostudies-literature | 2009 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Identification of ongoing human immunodeficiency virus type 1 (HIV-1) replication in residual viremia during recombinant HIV-1 poxvirus immunizations in patients with clinically undetectable viral loads on durable suppressive highly active antiretroviral therapy.

Shiu Carlum C   Cunningham Coleen K CK   Greenough Thomas T   Muresan Petronella P   Sanchez-Merino Victor V   Carey Vincent V   Jackson J Brooks JB   Ziemniak Carrie C   Fox Lawrence L   Belzer Marvin M   Ray Stuart C SC   Luzuriaga Katherine K   Persaud Deborah D  

Journal of virology 20090715 19


In most human immunodeficiency virus type 1 (HIV-1)-infected individuals who achieve viral loads of <50 copies/ml during highly active antiretroviral therapy (HAART), low levels of plasma virus remain detectable for years by ultrasensitive methods. The relative contributions of ongoing virus replication and virus production from HIV-1 reservoirs to persistent low-level viremia during HAART remain controversial. HIV-1 vaccination of HAART-treated individuals provides a model for examining low-lev  ...[more]

Similar Datasets

| S-EPMC4601916 | biostudies-literature
| S-EPMC4703306 | biostudies-literature
| S-EPMC4848790 | biostudies-literature
| S-EPMC3956871 | biostudies-literature
| S-EPMC5904142 | biostudies-literature
| S-EPMC4048224 | biostudies-literature
| S-EPMC2795168 | biostudies-literature
| S-EPMC5044815 | biostudies-literature
| S-EPMC4313209 | biostudies-literature
| S-EPMC7236356 | biostudies-literature